摘要
热休克蛋白90(Hsp90)是ATP依赖性的分子伴侣,参与客户蛋白(client protein)激活并促进其成熟,维持细胞多种蛋白的构象和功能,与细胞的增殖、凋亡、癌变和肿瘤发展密切相关,是很有希望的抗肿瘤药物的作用靶点之一。目前已有多个抗肿瘤Hsp90抑制剂进入Ⅰ/Ⅱ/Ⅲ期临床试验。该文综述以Hsp90为靶点的抗肿瘤药物研究进展。
Heat shock protein 90,a family of ATP-dependent chaperones that participate in activation and maturation of client proteins,maintain configurations and functions of multiple cell proteins.They closely correlate with cell proliferation,apoptosis,oncogenesis and tumor development,which make them one of the most promising biological targets for antitumor drugs.Till recently several Hsp90 inhibitors are undergoing phase Ⅰ,Ⅱ,or Ⅲ clinical trials.The advances in the development of antitumor drugs targeting Hsp90 were reviewed.
出处
《中国药物化学杂志》
CAS
CSCD
2010年第5期371-378,共8页
Chinese Journal of Medicinal Chemistry
基金
国家自然科学基金项目(30973639)
